Regenerative Medical Technology Group Inc. (RMTG)
OTCMKTS · Delayed Price · Currency is USD
0.0820
+0.0020 (2.50%)
At close: Sep 8, 2026
RMTG Revenue
Regenerative Medical Technology Group had revenue of $4.02M in the quarter ending June 30, 2026, with 309.10% growth. This brings the company's revenue in the last twelve months to $9.41M, up 94.32% year-over-year. In the year 2025, Regenerative Medical Technology Group had annual revenue of $5.10M with 24.17% growth.
Revenue (ttm)
9.41M
Revenue Growth
+94.32%
P/S Ratio
0.12
Revenue / Employee
9.41M
Employees
1
Market Cap
1.13M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.10M | 992.82K | 24.17% |
| Dec 31, 2024 | 4.11M | 1.70M | 70.44% |
| Dec 31, 2023 | 2.41M | 879.73K | 57.49% |
| Dec 31, 2022 | 1.53M | 1.09M | 249.46% |
| Dec 31, 2021 | 437.89K | 382.81K | 694.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Regenerative Medical Technology Group News
- 23 hours ago - RMTG's Cellgenic Division Begins Local Commercial Activity in Colombia, Subject to Colombian Regulatory Requirements - Accesswire
- 5 days ago - Cellgenic Establishes Local Commercial Presence in Brazil - Accesswire
- 7 days ago - RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its Latin American Footprint - Accesswire
- 12 days ago - RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International Regions - Accesswire
- 13 days ago - RMTG Acquires RMTG.com Domain and Launches New Investor-Focused Website, Advancing Shareholder Engagement - Accesswire
- 15 days ago - RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets - Accesswire
- 19 days ago - RMTG More Than Quadruples Revenue and Gross Profit in Q2 2026 Versus Q2 2025, With Operating Income Surpassing $560,000 - Accesswire
- 20 days ago - RMTG Provides Details for First-Ever Investor Call to Answer Shareholder Questions - Accesswire